Detalhe da pesquisa
1.
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Cell;
185(3): 467-484.e15, 2022 02 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35081335
2.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med;
384(20): 1885-1898, 2021 05 20.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33725432
3.
Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C.
J Infect Dis;
227(5): 610-621, 2023 03 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36130327
4.
Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus.
Clin Infect Dis;
76(2): 201-209, 2023 01 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36196614
5.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet;
399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35691324
6.
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Lancet;
399(10324): 521-529, 2022 02 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35074136
7.
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Lancet;
399(10319): 36-49, 2022 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34883053
8.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol;
211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36729167
9.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet;
398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34480858
10.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet;
397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33798499
11.
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
Lancet;
398(10318): 2258-2276, 2021 12 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34863358
12.
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
Lancet;
398(10303): 856-869, 2021 09 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34370971
13.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet;
397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33306989
14.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet;
396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33220855
15.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet;
397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33617777
16.
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Lancet;
396(10249): 467-478, 2020 08 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32702298
17.
Nicotinic acid adenine dinucleotide phosphate (NAADP) is a second messenger in muscarinic receptor-induced contraction of guinea pig trachea.
J Biol Chem;
288(16): 10986-93, 2013 Apr 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23467410
18.
Nicotinic acid adenine dinucleotide phosphate regulates skeletal muscle differentiation via action at two-pore channels.
Proc Natl Acad Sci U S A;
107(46): 19927-32, 2010 Nov 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21041635
19.
A Randomized Trial Assessing the Immunogenicity and Reactogenicity of Two Hexavalent Infant Vaccines Concomitantly Administered With Group B Meningococcal Vaccine.
Pediatr Infect Dis J;
42(1): 66-73, 2023 01 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36476534
20.
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults.
Hum Vaccin Immunother;
19(2): 2233400, 2023 08 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37438960